부산대학교 도서관

Simple Summary: Quality of life is significantly impaired among individuals with inflammatory bowel disease (IBD), and the growth performance of animals is also affected by IBD. However, the side effects and poor therapeutic effects of medications for IBD limit the treatment effect. In this study, we demonstrated that oral administration of surfactin containing Bacillus licheniformis-fermented products (SBLF) alleviates dextran sulfate sodium-induced colitis in mice by reducing inflammatory responses and the NLRP3 inflammasome activation in colon tissue. Inflammatory bowel disease (IBD) is a non-infectious disease characterized by chronic inflammation of the gastrointestinal tract. Currently, management of IBD is still a clinical challenge. The purpose of this study was to investigate the therapeutic potential of surfactin containing Bacillus licheniformis-fermented products (SBLF) and commercial surfactin (CS) on the treatment of dextran sulfate sodium (DSS)-induced colitis in a mouse model. We found that mice that received drinking water containing 3% DSS developed significant colitis symptoms, including increased disease activity index, body weight loss, shortening of the colon length, splenomegaly, colonic inflammation and colonic NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome activation. Notably, orally received SBLF, CS or clinical anti-inflammatory drug 5-aminosalicylic acid improved DSS-induced colitis symptoms in mice. These findings show that SBLF can improve IBD in mice by reducing colonic inflammation and inhibiting the NLRP3 inflammasome activation, suggesting that SBLF has the potential to be used as a nutraceutical in humans or a feed additive in economic and companion animals for preventing IBD. [ABSTRACT FROM AUTHOR]